<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116151</url>
  </required_header>
  <id_info>
    <org_study_id>Alantel</org_study_id>
    <nct_id>NCT04116151</nct_id>
  </id_info>
  <brief_title>Effectiveness of a Cream for Treatment of Dermatitis in Patients Whith Cancer</brief_title>
  <acronym>Alantel-</acronym>
  <official_title>Effectivenes and Safety of a Cream of Aloe Vera, Camomila and Tomillo (Alantel) for Profilaxis or Treatmment of Deratitis by Radiotheraphy in Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Reina Sofia de Cordoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Reina Sofia de Cordoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is intended to evaluate the effect of a marketed cream (Alantel®) based on natural&#xD;
      products at high concentrations for the preventive and curative treatment (early stages) of&#xD;
      radiation-induced dermatitis in cancer patients. For this, an experimental, prospective,&#xD;
      controlled clinical trial, with two parallel arms, double blind, multicentre, will be carried&#xD;
      out in which doctors will recruit 78 patients aged 14 years or over in Primary Care&#xD;
      consultations. more, diagnosed with cancer, and having received radiotherapeutic cancer&#xD;
      treatment, being randomly assigned to the experimental group (cosmetic cream) or the control&#xD;
      group (placebo cream). The main variable will be the incidence rate of mild&#xD;
      post-translational dermatitis and its improvement or cure once it has been established.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental, prospective, controlled clinical trial, with two parallel arms, double blind, multicenter study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Double blind: both the patient and the healthcare professional do not know if the cream to be tested or the placebo is applied</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of radiation-induced dermatitis</measure>
    <time_frame>three weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analog visual scale</measure>
    <time_frame>three weeks</time_frame>
    <description>Analog visual scale from 0 to 10 points to assess the symptomatology perceived by the patient (pain, stinging, ..)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>DERMATITIS INDUCED BY RADIOTHERAPY IN PATIENTS WHITH CANCER</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local administration of the Alantel (R) cream on the affected skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Local administration of the Placebo cream on the affected skin</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)</intervention_name>
    <description>Application on the affected skin of the cream to be tested</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Harmless moisturizing substance</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 14 years of age or older&#xD;
&#xD;
          -  Diagnosed with cancer and who are or have recently received radiotherapy treatment.&#xD;
&#xD;
          -  We will include patients without dermatitis or with acute dermal posttradiotherapy&#xD;
             lesions, in grades 1 and 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with dermal lesions in grade greater than 2.&#xD;
&#xD;
          -  Skin cancer invasion or distant tumor metastasis.&#xD;
&#xD;
          -  Concurrent chemotherapy with RT, severe / extensive burns, moisture, erosion or&#xD;
             suppuration in the skin, history of connective tissue disorders, severe mental&#xD;
             disorder (dementia, drug addiction, etc.).&#xD;
&#xD;
          -  History of hypersensitivity reaction to any of the ingredients of the studio cream.&#xD;
&#xD;
          -  Participants involved in other clinical trials within that month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Family Medicine Teaching Unit and Community</name>
      <address>
        <city>Córdoba</city>
        <zip>14011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Reina Sofia de Cordoba</investigator_affiliation>
    <investigator_full_name>Luis A Perula</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>CANCER</keyword>
  <keyword>DERMATITIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

